Ablation Technology Market : Global Industry Analysis and Opportunity Assessment, 2036

Ablation Technology Market Size, Market Forecast and Outlook by FMI

The ablation technology market was valued at USD 6.8 billion in 2025 and is projected to reach USD 7.4 billion in 2026. It is forecast to reach USD 17.4 billion by 2036 at 8.9% CAGR. Radiofrequency ablators are projected to lead the product segment with 46.0% share, while cardiovascular disease treatment is expected to hold 25.0% share by application in 2026.

Summary of the Ablation Technology Market

• Demand and Growth Drivers
  • Procedure volumes are supported by atrial fibrillation and cancer burden. Chronic pain and abnormal uterine bleeding add secondary use pools in major healthcare systems.
  • Cardiac use is widening as pulsed field ablation gives electrophysiology labs a tissue-selective option for rhythm treatment.
  • Oncology use is supported by liver and kidney cancer cases. Lung, bone and prostate procedures add separate use paths where local tissue destruction can avoid open surgery.
  • Hospital buyers compare energy precision and image guidance first. Catheter control and service response affect final ablation platform selection.
• Product and Segment View
  • Radiofrequency ablators are projected to account for 46.0% share in 2026 as cardiac and pain procedures already use installed RF workflows.
  • Cardiovascular disease treatment is expected to hold 25.0% share in 2026 as arrhythmia care creates steady catheter use.
  • Pulsed field systems are expanding fastest from a smaller starting point as companies receive approvals in the United States, Japan and Europe.
  • The sector shares capital planning with electrophysiology and microwave ablation device sectors through shared hospital capital spending.
• Geography and Competitive Outlook
  • Japan is projected to record 10.6% CAGR through 2036 as aging care needs and oncology procedure depth support device use.
  • The United Kingdom is expected to post 9.8% CAGR through 2036 as National Health Service funding routes support specialist ablation services.
  • Medtronic plc, Boston Scientific Corporation and Johnson & Johnson MedTech shape cardiac ablation choices through approvals and mapping ecosystems.
  • AngioDynamics, EDAP TMS and Stryker widen exposure beyond rhythm care through prostate, ultrasound and pain-related ablation systems.
• Analyst Opinion
  • Sudip saha, Principal Consultant for Technology at FMI says, “Ablation technology is no longer a single product discussion. Hospitals are buying confidence around lesion control and service uptime. The next phase will favor suppliers that prove procedure reliability in one clinical area and then carry that trust into adjacent applications. Cardiac ablation gives the market its largest repeat procedure base, while oncology and pain care give suppliers room to build more targeted systems.”
• Ablation Technology Market Value Analysis
  • The market is moving from energy generators alone toward procedure platforms that include catheters and probes. Software and service contracts now shape buyer comparisons.
  • Cardiac ablation carries repeat hospital demand because atrial fibrillation care needs mapping, access tools and trained lab teams.
  • Oncology ablation adds a separate route through interventional radiology departments that treat liver, kidney and lung lesions.
  • The United States Food and Drug Administration listed several ablation approvals during 2024, which supports near-term platform competition. The United States Food and Drug Administration listed the Sphere-9 Catheter and Affera Ablation System in March 2025. This supports near-term platform competition.

Treatment teams need ablation tools that destroy target tissue while limiting avoidable injury. In January 2024, FDA approved FARAPULSE under PMA P230030 for pulmonary vein isolation in drug-refractory recurrent symptomatic paroxysmal atrial fibrillation. That approval gives hospitals a clearer path for non-thermal cardiac ablation adoption.

Procedure flow is also changing inside electrophysiology labs. In March 2025, FDA stated that Sphere-9 Catheter and Affera Ablation System was approved on October 24 2024 for mapping and treatment of persistent atrial fibrillation lasting less than 1 year. That supports labs seeking fewer separate systems during cardiac procedures.

Cancer care adds another route for technology expansion. In June 2025, CMS stated that HCPCS code C8005 covers transbronchial ablation of lung tumors using pulsed electric field energy. That payment structure helps hospitals evaluate PEF lung tumor programs with clearer billing logic. Suppliers with approved devices and safety documentation are better placed for clinical adoption.

Ablation Technology Market Definition

The ablation technology market covers medical devices that use controlled energy to destroy or modify targeted tissue. Scope includes radiofrequency and microwave systems. Cryoablation and laser systems are also counted. Pulsed field, ultrasound and hydrothermal systems are included when sold for clinical tissue treatment. Revenue covers generators and catheters. It also includes probes and electrodes. Disposables and software modules are counted in commercial clinical care. Service contracts are included when tied to ablation systems. The market includes the related ablation devices sector where instruments and consumables are sold for tissue destruction procedures.

Ablation Technology Market Inclusions

Market scope covers hospital and outpatient systems used in cardiovascular and oncology procedures. Gynecology and urology procedures are included. Pain management and neurological procedures are included. Product coverage includes ablation catheters and RF generators. Microwave generators and cryoprobes are included. HIFU platforms, electroporation systems and lesion guidance software are included. The scope includes installed systems and single-use procedure components when sold for medical ablation.

Ablation Technology Market Exclusions

Scope does not include cosmetic skin energy devices or industrial ablation equipment. Dental lasers and general surgical cautery tools are excluded. Research prototypes are excluded when not sold for clinical use. Revenue from hospital construction, imaging rooms and routine diagnostic mapping is excluded unless the product is packaged with an ablation procedure system. Drug therapy and radiation therapy are outside the counted revenue base. Open surgical instruments are excluded unless sold as part of an ablation procedure system.

Ablation Technology Market Research Methodology

• Primary Research: FMI analysts reviewed hospital procedure needs and cardiology service buying patterns. Oncology intervention pathways and supplier portfolio depth were checked in major countries.
• Desk Research: The study used public data from health agencies and disease burden bodies. Regulators and company releases supported the evidence checks. Official clinical sources were reviewed separately.
• Market sizing and forecasting: Market size was estimated through a hybrid top-down and bottom-up model using published FMI anchors and procedure growth checks.
• Data validation: Forecast checks compared country disease burden with 2024 and 2025 approvals. Company launches and adjacent therapy spending signals were reviewed separately.

Why is the Ablation Technology Market Growing?

• Atrial fibrillation care is pushing hospitals toward catheter platforms that shorten rhythm procedure workflow and improve lesion confidence.
• Cancer care is adding local tissue destruction for patients who need less invasive treatment or repeat local control.
• Pain and gynecology procedures support outpatient demand because radiofrequency and thermal tools can fit shorter care pathways.

The Centers for Disease Control and Prevention estimated in May 2024 that 12.1 million people in the United States will have atrial fibrillation by 2050. This matters because AF is one of the main repeat-use clinical areas for catheter ablation. Hospitals that build electrophysiology lab capacity usually buy catheters and generators together. Sheaths and mapping support follow the same platform decision. That platform buying pattern supports a wider revenue base than the sale of a single catheter.

The International Agency for Research on Cancer stated in February 2024 that there were almost 20 million new cancer cases in 2022. It also projected to have more than 35 million new cancer cases by 2050. Those numbers do not translate directly into ablation procedures or device orders. They show why cancer centers keep investing in local treatment tools for liver and lung tumors. Kidney, bone and prostate tumors add further procedure routes. Ablation use rises when clinical teams can target tissue and limit open surgery risk.

Market Segmentation Analysis

• Radiofrequency ablators are projected to reach 46.0% share in 2026 as the installed base spans cardiac, pain and oncology procedures.
• Cardiovascular disease treatment is expected to represent 25.0% share in 2026 as rhythm care remains the most repeatable use base.
• Hospitals are forecast to account for 62.0% share in 2026 because complex procedures need imaging, anesthesia support and trained staff.
• Catheter-based procedures are estimated to hold 48.0% share in 2026 as cardiac ablation drives high-value single-use component demand.
• Direct hospital tender sales are estimated at 57.0% share in 2026 as capital systems and procedure disposables are bought together.

The market for ablation technology is divided into six primary segment groups. Those groups cover product and application. End use and procedure approach add a second lens. Energy modality and sales model explain how hospitals evaluate systems. Product categories include radiofrequency ablators and laser ablators. Ultrasound and electrical ablators complete the electrical energy view. Cryoablation systems and microwave ablators form the other product groups. Application covers cardiovascular disease treatment and cancer treatment. Pain management and gynecology form the second use group. Urology and neurology complete the clinical view. This structure meets the five-segment minimum and reflects how hospitals compare clinical use, energy source and buying route.

Insights into the Radiofrequency Ablators Product Segment

• Radiofrequency ablators are projected to account for 46.0% share of product demand in 2026. Installed cardiac and pain workflows keep RF use broad.
• Hospitals keep RF platforms in service because staff training, generator familiarity and reimbursement pathways already exist in core procedures.

Insights into the Cardiovascular Disease Treatment Application Segment

• Cardiovascular disease treatment is expected to represent 25.0% share of application demand in 2026. Rhythm care creates repeat catheter and mapping use.
• Pulsed field ablation is changing cardiac buying criteria from heat control toward tissue selectivity and integration with mapping systems.

Insights into the Hospitals End Use Segment

• Hospitals are forecast to account for 62.0% share of end-use demand in 2026. Complex cases need imaging rooms and specialist clinical support.
• Ambulatory centers gain share in pain and gynecology procedures where case risk and recovery needs fit same-day care.

Insights into the Catheter-Based Procedure Approach Segment

• Catheter-based procedures are estimated to account for 48.0% share of procedure approach demand in 2026.
• Percutaneous probes remain important in oncology because interventional radiologists need access routes that avoid open surgery.

Insights into the Thermal Energy Modality Segment

• Thermal modalities are estimated to account for 54.0% share of energy modality demand in 2026.
• Non-thermal systems are expanding from a smaller starting point as pulsed field and irreversible electroporation products gain regulatory traction.

Insights into the Direct Hospital Tender Sales Model Segment

• Direct hospital tender sales are estimated to account for 57.0% share in 2026. Capital platforms and disposables are often negotiated together.
• Distributors retain a role in lower-volume countries where hospitals need local training and payment support.

Ablation Technology Market Drivers, Restraints, and Opportunities

• Cardiac rhythm procedure demand is raising the need for mapping-linked ablation platforms in specialist hospitals.
• Capital cost and training time constrain use in hospitals with low procedure volume or limited specialist staff.
• New indications in prostate and gynecology create room for specialist systems outside electrophysiology labs.

Ablation technology demand is supported by the movement of care toward targeted tissue treatment. The United States Food and Drug Administration page for the Sphere-9 Catheter and Affera Ablation System describes its use for atrial fibrillation and typical atrial flutter. That type of approval gives hospitals a clearer route to evaluate platforms that combine mapping and ablation. It also raises the standard for evidence because buyers compare clinical endpoints as much as device design.

Capital Cost Limits Smaller Programs

A notable market restraint is not clinical interest. The restraint is the cost of full procedure readiness. A hospital needs generators and imaging access before it can use ablation systems at scale. Trained staff and service cover decide whether case volumes can rise. Smaller centers can buy probes for selected cases, but they often delay platform changes until referral volumes justify the investment.

New Energy Platforms Create Upside

A lucrative opportunity is in systems that reduce procedure friction without asking hospitals to rebuild the room. Boston Scientific received United States Food and Drug Administration approval for FARAPULSE in January 2024. Johnson & Johnson MedTech received United States Food and Drug Administration approval for VARIPULSE in November 2024. These approvals show how cardiac ablation competition is shifting toward platform integration and operator workflow.

Analysis of Ablation Technology Market by Key Countries

Country	CAGR
United States	9.3%
United Kingdom	9.8%
Germany	5.0%
Japan	10.6%
China	9.7%
India	5.0%
South Korea	6.7%

Source: Future Market Insights, 2026.

Ablation Technology Market CAGR Analysis by Country

• Japan is projected to lead at 10.6% CAGR through 2036 as aging care needs and specialist procedure capacity support device use.
• The United Kingdom is expected to post 9.8% CAGR through 2036 as specialist National Health Service service lines support ablation access.
• China is projected to grow at 9.7% CAGR through 2036 as oncology burden and tertiary hospital investment support procedure growth.
• The United States is projected at 9.3% CAGR through 2036 as FDA approvals and electrophysiology lab depth support premium platforms.
• South Korea, Germany and India remain important markets, with growth shaped by reimbursement depth and specialist center capacity.

Demand for ablation technology is forecast to rise at 8.9% CAGR from 2026 to 2036. Country-level analysis covers markets where arrhythmia care and oncology care affect platform buying. Procedure reimbursement and specialist hospital capacity add further pressure. Japan, the United Kingdom and China track above the global average. Each market has a clearer pathway for specialist procedure use.

Demand Outlook for Ablation Technology Market in the United States

The United States has deep electrophysiology lab capacity and a clear approval route for new ablation platforms. The United States is projected to record a 9.3% CAGR through 2036, supported by frequent rhythm care use and new device approvals. The Centers for Disease Control and Prevention estimated 12.1 million people in the United States will have atrial fibrillation by 2050. Hospitals in Boston, Houston and California will keep comparing platform evidence against procedure time and service support.

• Boston cardiac centers can evaluate pulsed field systems where electrophysiology teams already use mapping platforms daily.
• Houston cancer programs can add percutaneous tumor ablation where interventional radiology supports liver and lung procedures.
• California outpatient pain centers can use RF nerve ablation where same-day care pathways are already established.

Future Outlook for Ablation Technology Market in the United Kingdom

National Health Service procedure funding creates a defined route for specialist ablation services. The United Kingdom is expected to expand at 9.8% CAGR through 2036, supported by cardiac and oncology service pathways. The International Agency for Research on Cancer recorded 50,700 lung cancer cases and 49,429 colorectal cancer cases in the United Kingdom in 2022. Supplier success are likely to depend on evidence packages that fit NHS budget review and clinical governance needs.

• London tertiary hospitals create demand for mapping-linked rhythm procedures in specialist cardiac units.
• Manchester oncology services can use local ablation for patients who need targeted tumor control.
• Birmingham pain clinics can compare RF systems by case time and service response.

Opportunity Analysis of Ablation Technology Market in Germany

Germany is forecast to grow at 5.0% CAGR through 2036, with demand tied to specialist procedure concentration. The International Agency for Research on Cancer recorded 62,544 colorectal cancer cases and 62,025 lung cancer cases in Germany in 2022. Steady growth would need clearer evidence that newer systems reduce time or complication risk enough to justify replacement.

• Stuttgart cardiac centers can assess pulsed field systems for atrial fibrillation cases in specialist labs.
• Munich oncology hospitals can use thermal ablation in liver and kidney intervention pathways.
• Berlin hospital groups will compare service contracts before switching generators or catheter systems.

In-depth Analysis of Ablation Technology Market in Japan

Japan’s aging population gives ablation technology a broad clinical base in cardiac and cancer care. Japan is expected to advance at 10.6% CAGR through 2036, supported by older patient needs and procedure capacity. The International Agency for Research on Cancer recorded 145,756 colorectal cancer cases and 136,723 lung cancer cases in Japan in 2022. Suppliers that support careful training and domestic regulatory documentation are better placed here.

• Tokyo hospitals can use catheter ablation where rhythm specialists manage high case loads.
• Osaka cancer centers can apply microwave and RF ablation in liver and lung tumor care.
• Fukuoka hospital networks need vendor training support before shifting from familiar RF systems.

Sales Analysis of Ablation Technology Market in China

China’s demand is shaped by cancer burden and the expansion of tertiary care capacity. China is projected to rise at 9.7% CAGR through 2036, supported by oncology volume and cardiac procedure growth. The International Agency for Research on Cancer recorded 1,060,584 lung cancer cases and 517,106 colorectal cancer cases in China in 2022. Local service reach and price discipline will decide which suppliers convert the clinical need into repeat orders.

• Shanghai tertiary hospitals can use ablation platforms in interventional oncology and cardiac rhythm service lines.
• Guangzhou cancer centers can widen use of local tissue destruction for liver and lung lesions.
• Chengdu hospitals may prefer suppliers that provide training and maintenance near western China care hubs.

In-depth Analysis of Ablation Technology Market in India

India has high clinical need but uneven access to specialist ablation infrastructure. India is forecast at 5.0% CAGR through 2036, constrained by capital cost and specialist staff availability. The International Agency for Research on Cancer recorded 1,413,316 new cancer cases in India in 2022. Volume can improve if private hospital groups expand catheter labs and interventional oncology rooms outside the largest cities.

• Delhi National Capital Region hospitals can add cardiac ablation capacity where private specialty care is concentrated.
• Mumbai oncology centers can use local tumor ablation where image-guided intervention rooms are available.
• Bengaluru hospital groups can build training pools for electrophysiology and interventional radiology staff.

Sales Analysis of Ablation Technology Market in South Korea

South Korea combines specialist hospitals with domestic strength in imaging and electronics. South Korea is expected to post 6.7% CAGR through 2036, with growth lower than Japan because the market is more concentrated. The International Agency for Research on Cancer recorded 31,337 lung cancer cases and 29,560 colorectal cancer cases in South Korea in 2022. Suppliers can win through platform integration, but the addressable country base is smaller than China or Japan.

• Seoul hospitals can test integrated cardiac ablation systems within high-volume specialist centers.
• Busan oncology providers can use ablation in liver and lung cases that need local control.
• Daegu care networks may rely on distributor support for service and inventory coverage.

Competitive Landscape and Strategic Positioning

• Competition is concentrated in companies that combine energy delivery and mapping support. Clinical evidence and global service coverage decide wider hospital trust.
• Medtronic plc, Boston Scientific Corporation and Johnson & Johnson MedTech set the pace in cardiac ablation platform approvals.
• Specialist firms compete in prostate, tumor and pain procedures where focused indications matter more than broad catheter portfolios.
• Entry barriers include clinical evidence and regulatory approval. Physician training and sterile supply add practical limits. Hospital service coverage remains a separate barrier.

Medtronic plc strengthened its cardiac position when the Affera Mapping and Ablation System and Sphere-9 Catheter received United States Food and Drug Administration approval in October 2024. The approval matters because it links mapping and ablation inside one workflow. Hospitals evaluate that link closely when procedure rooms are busy. Medtronic also benefits from its established cryoablation and RF base, which lets sales teams discuss multiple energy paths with the same clinical department.

Boston Scientific Corporation competes through fast pulsed field ablation expansion. The FARAPULSE platform received United States Food and Drug Administration approval in January 2024 and later gained a wider persistent atrial fibrillation label in July 2025. The company also introduced mapping-linked catheter updates during 2024. That product path supports hospitals that want fewer device exchanges and clearer procedure visualization. The related electrophysiology equipment and recording systems segment shows how mapping and recording tools affect ablation buying decisions.

AngioDynamics, EDAP TMS and Stryker compete where the buyer problem is not atrial fibrillation. AngioDynamics received United States Food and Drug Administration clearance for NanoKnife prostate tissue ablation in December 2024. EDAP TMS launched AI-assisted Focal One robotic HIFU procedures with Avenda Health in September 2024. Stryker received United States Food and Drug Administration clearance for OptaBlate BVN in May 2025. These moves widen the market beyond cardiac labs into urology, oncology and pain care.

Key Companies in the Ablation Technology Market

Competition is best read by clinical role. Cardiac and oncology buyers do not evaluate the same proof points as pain and urology programs.

• Cardiac Platform Leaders: Medtronic plc and Boston Scientific Corporation compete through catheter portfolios and mapping links. Johnson & Johnson MedTech and Abbott Laboratories add global approval depth.
• Oncology and Urology Specialists: AngioDynamics, EDAP TMS and Sonablate Corp. compete around tissue targeting, imaging fit and procedure preservation goals.
• Pain and Interventional Care Specialists: Stryker Corporation and related interventional spine suppliers compete on RF generators, access tools and procedure support.

Competitive Benchmarking: Ablation Technology Market

Company	Cardiac Platform Depth	Image Guidance Fit	Clinical Evidence Support	Geographic Footprint
Medtronic plc	High	Strong	Strong	Global with cardiac and cryoablation depth
Boston Scientific Corporation	High	Strong	Strong	Global with fast pulsed field expansion
Johnson & Johnson MedTech	High	Strong	Strong	Global with CARTO mapping integration
Abbott Laboratories	Medium	Strong	Medium	Global with Volt and RF catheter platforms
AngioDynamics Inc.	Medium	Medium	Strong	North America and Europe with NanoKnife focus
EDAP TMS SA	Medium	Strong	Strong	Europe and United States with HIFU focus
Stryker Corporation	Medium	Medium	Medium	North America centered in interventional pain
Sonablate Corp.	Low	Medium	Medium	Urology focused across more than 50 countries

Source: Future Market Insights competitive analysis, 2026. Ratings reflect relative positioning based on ablation portfolio fit, imaging support and clinical evidence strength.

Key Developments in Ablation Technology Market

• In March 2025, Abbott Laboratories received CE Mark in Europe for the Volt pulsed field ablation system.
• In December 2024, AngioDynamics Inc. received United States Food and Drug Administration clearance for NanoKnife prostate tissue ablation.
• In May 2025, Stryker Corporation received United States Food and Drug Administration clearance for the OptaBlate BVN system.

Key Players in the Ablation Technology Market

Major Global Players:

• Medtronic plc
• Boston Scientific Corporation
• Johnson & Johnson MedTech
• Abbott Laboratories
• Stryker Corporation

Specialist and Regional Players:

• AngioDynamics Inc.
• EDAP TMS SA
• Sonablate Corp.
• AtriCure Inc.
• Olympus Corporation
• Hologic Inc.

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 7.4 billion to USD 17.4 billion, at 8.9% CAGR
Market Definition	Medical ablation energy platforms and procedure components used to destroy or modify targeted tissue
Product	Radiofrequency Ablators, Laser Ablators, Ultrasound Ablators, Electrical Ablators, Cryoablation Systems, Microwave Ablators
Application	Cardiovascular Disease Treatment, Cancer Treatment, Pain Management, Gynecology, Urology, Neurology
End Use	Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Cancer Centers
Procedure Approach	Catheter-Based, Percutaneous, Laparoscopic, Endoscopic, Noninvasive
Energy Modality	Thermal, Non-Thermal, Cryogenic, Ultrasound-Based
Sales Model	Direct Hospital Tender, Distributor Sales, Group Purchasing, Service Bundles
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	United States, United Kingdom, Germany, Japan, China, India, South Korea, and 30 plus countries
Key Companies Profiled	Medtronic, Boston Scientific, Johnson & Johnson MedTech, Abbott, AngioDynamics, EDAP TMS, Stryker, Sonablate
Forecast Period	2026 to 2036
Approach	Hybrid top-down and bottom-up methodology using FMI anchors, disease burden checks, regulatory approvals and supplier developments

Market Analysis by Segments

By Product:

• Radiofrequency Ablators
• Laser Ablators
• Ultrasound Ablators
• Electrical Ablators
• Cryoablation Systems
• Microwave Ablators

By Application:

• Cardiovascular Disease Treatment
• Cancer Treatment
• Pain Management
• Gynecology
• Urology
• Neurology

By End Use:

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Cancer Centers

By Procedure Approach:

• Catheter-Based
• Percutaneous
• Laparoscopic
• Endoscopic
• Noninvasive

By Energy Modality:

• Thermal
• Non-Thermal
• Cryogenic
• Ultrasound-Based

By Sales Model:

• Direct Hospital Tender
• Distributor Sales
• Group Purchasing
• Service Bundles

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• East Asia
• South Asia and Pacific
• Middle East and Africa

Research Sources and Bibliography

• Centers for Disease Control and Prevention. (2024, May 14). About Atrial Fibrillation.
• International Agency for Research on Cancer. (2024, February 1). Global cancer burden growing, amidst mounting need for services.
• United States Food and Drug Administration. (2025, March 5). Sphere-9 Catheter and Affera Ablation System - P240013.
• Medtronic plc. (2024, October 24). Medtronic receives FDA approval of Affera Mapping and Ablation System and Sphere-9 Catheter.
• Boston Scientific Corporation. (2024, January 31). Boston Scientific receives FDA approval for FARAPULSE Pulsed Field Ablation System.
• Johnson & Johnson. (2024, November 7). Johnson & Johnson MedTech receives FDA approval for the VARIPULSE Pulsed Field Ablation Platform for the treatment of atrial fibrillation.
• Abbott Laboratories. (2025, March 27). Abbott receives CE Mark for its Volt Pulsed Field Ablation System to treat patients with abnormal heart rhythms.
• AngioDynamics Inc. (2024, December 9). AngioDynamics receives FDA clearance for the NanoKnife System for prostate tissue ablation.
• EDAP TMS SA. (2024, September 19). EDAP and Avenda Health launch world’s first AI-assisted Focal One robotic HIFU procedures.
• Stryker Corporation. (2025, May 19). Stryker receives FDA clearance for OptaBlate BVN Basivertebral Nerve Ablation System.
• International Agency for Research on Cancer. (2024, February 8). United States of America fact sheet: GLOBOCAN 2022.
• International Agency for Research on Cancer. (2024, February 8). China fact sheet: GLOBOCAN 2022.
• International Agency for Research on Cancer. (2024, February 8). India fact sheet: GLOBOCAN 2022.
• International Agency for Research on Cancer. (2024, February 8). United Kingdom fact sheet: GLOBOCAN 2022.

The bibliography is provided for reader reference and uses government and public health sources. Regulator, company and FMI sources support ablation technology demand signals.

This Report Answers

• What is the current and future size of the ablation technology market?
• How fast is the ablation technology market expected to expand between 2026 and 2036?
• Which product type is expected to lead ablation technology demand by 2026?
• Which application is projected to account for the largest ablation technology share in 2026?
• Why do cardiac rhythm procedures matter for this market?
• How do cancer care and pain care affect non-cardiac ablation demand?
• Which countries are projected to record faster expansion during the forecast period?
• Who are the main companies active in ablation technology?
• How does FMI define the ablation technology market scope?
• How does FMI estimate and validate the ablation technology forecast?